Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 516-524

  Gialeli, Ch ^a,d   Theocharis, A D ^a   Kletsas, D ^b   Tzanakakis, G N ^c   Karamanos, N K ^a,d  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

Colorectal cancer; Epidermal growth factor; Panitumumab; Solid tumors

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EXTRACELLULAR METALLOPROTEINASES INDUCER; FOCAL ADHESION KINASE; MEMBRANE TYPE 1 METALLOPROTEINASE; METALLOPROTEINASE; PANITUMUMAB; SYNDECAN 4; UNCLASSIFIED DRUG; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; EMMPRIN GENE; ENZYME ACTIVITY; GAPDH GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MT1 MMP GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYNDECAN 4 GENE; TUMOR INVASION; UPA GENE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 14; RECEPTOR, EPIDERMAL GROWTH FACTOR; SYNDECAN-4; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WOUND HEALING;

EID: 84879076343     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9875-x     Document Type: Article

References (32)

1. Leserer M, Gschwind A, Ullrich A (2000) Epidermal growth factor receptor signal transactivation. IUBMB Life 49(5):405-409. doi: 10.1080/152165400410254
2. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G (2005) Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16(2):189-194. doi: 10.1093/annonc/mdi057
3. Yarden Y (2001) The EGFR family and its ligands in human cancer: signaling mechanisms and opportunities. Eur J Cancer 37(4):S3-S8. doi: 10.1016/S0959-8049(01)00230-1
4. Iozzo RV, Karamanos N (2010) Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 277(19):3863. doi: 10.1111/j.1742-4658.2010.07796.x
5. Nagase H, Karamanos N (2011) Metalloproteinases in health and disease: challenges and the future prospects. FEBS J 278(1):1. doi: 10.1111/j.1742-4658. 2010.07917.x
6. Hascall V, Karamanos N (2011) Regulatory roles of hyaluronan in health and disease. FEBS J 278(9):1411. doi: 10.1111/j.1742-4658.2011.08068.x
7. Woods A, Couchman JR (2001) Syndecan 4 and focal adhesion function. Curr Opin Cell Biol 13:578-583. doi: 10.1016/S0955-0674(00)00254-4
8. Gialeli C, Theocharis AD, Karamanos NK (2011) Matrix metalloproteinases in health and disease: roles in cancer progression and their pharmacological targeting. FEBS J 278:16-27. doi: 10.1111/j.1742-4658.2010.07919.x
9. Stahtea NX, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D, Karamanos NK (2007) Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP-2 activation. Int J Cancer 121(12):2808-2814. doi: 10.1002/ijc.23029
10. Jin JS, Wu CY, Lin YF, Wang JY, Yu CP, Sheu LF, Chiang H, Tsai WC, Lee WH (2006) Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers 22(5-6):309-316
11. Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F (2003) Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 63:7575-7580
12. Morgan H, Hill PA (2005) Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Canc Cell Int 5:1. doi: 10.1186/1475-2867-5-1
13. Wu M, Rivkin A, Pham T (2008) Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Therap 30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014
14. Van Custem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664. doi: 10.1200/JCO.2006.08.1620
15. Gialeli C, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN, Karamanos NK (2009) Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr Med Chem 16:3797-3804. doi: 10.2174/092986709789177984
16. Nikitovic D, Pratsinis H, Berdiaki A, Gialeli C, Kletsas D, Tzanakakis GN (2012) Growth factor signaling and extracellular matrix. In: Karamanos NK (ed) Extracellular matrix: pathobiology and signaling. De Gruyter, Berlin, pp 741-753
17. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C (2006) In vivo and in vitro antitumor activity of Oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Canc Chemother Pharmacol 57(6):709-718. doi: 10.1007/s00280-005-0123-3
18. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953-1961. doi: 10.1158/0008-5472.CAN-07-5659
19. Siddiqui AD, Piperdi B (2010) KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17(4):1168-1176. doi: 10.1245/s10434-009-0811-z
20. Fears CY, Woods A (2006) The role of syndecans in disease and wound healing. Matrix Biol 25:443-456. doi: 10.1016/j.matbio.2006.07.003
21. You B, Chen EX (2012) Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol 52:128-155
22. Peeters M, Price TJ, Cervantes A, et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706-4713. doi: 10.1177/0091270010395940
23. Douillard JY, Siena S, Cassidy J, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697-4705. doi: 10.1200/JCO.2009.27.4860
24. Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634. doi: 10.1200/JCO.2007.14.7116
25. Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14(1):77-94. doi: 10.1517/14728220903460340
26. Hauck C, Sieg D, Hsia D, Loftus J, Gaarde W, Monia BP, Schlaepfer DD (2001) Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 61:7079. doi: 10.1242/jcs.00373
27. Lu Z, Jiang G, Blume-Jensen P, Hunter T (2001) Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21(12):4016. doi: 10.1128/MCB.21.12.4016-4031.2001
28. Sounni NE, Noel A (2005) Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87:329-342. doi: 10.1016/j.biochi.2004.07.012
29. Weaver MA (2006) Invadopodia: specialized cell structures of cancer invasion. Clin Exp Metast 23:97-105. doi: 10.1007/s10585-006-9014-1
30. Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S, Cao J (2011) Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 286(38):33167-33177. doi: 10.1074/jbc.M111.256644
31. Jo M, Thomas KS, O'Donnell DM, Gonias SL (2003) Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 278:1642-1646. doi: 10.1074/jbc.M210877200
32. Liu D, Ghiso JA, Estrada Y, Ossowski L (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Canc Cell 1:445-457. doi: 10.1016/S1535-6108(02)00072-7